Argent BioPharma Ltd raised $4,500,000 via Investing.com

Perth, Australia, January 7, 2025 /PRNewswire/ — Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) is a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuroimmunomodulation and advanced nanotechnologies. Medical technology.

The company announces the successful completion of 4,500,000 US dollars (before costs) capital increase (Placement) through a subscription of 5,625,000 units, at the price of each 0.80 USD (~ 1.28 Australian dollars). Each unit consists of two (2) fully paid ordinary shares (Placement shares) and one (1) free attach order, exercisable at 0.55 USD (~0.88 AUD(with the expiration of a period of three years from the date of issuance)orders).

The offering will be conducted in two tranches: Slide 1: The 5,000,000 Subscription Shares and 2,500,000 Warrants will be issued immediately, utilizing the Company’s existing subscription capacity under ASX Listing Rules 7.1 and 7.1A. Slide 2: 6,250,000 subscription shares and 3,125,000 warrants will be issued subject to shareholder approval at an upcoming general meeting.

The subscription shares will be issued at a price 0.40 USD (~0.64 AUD), which represents approximately: 370% of the 15-day VWAP 0.173 Australian dollarsand 377% to the last closing price of 0.17 Australian dollars Before the stock enters a trading halt January 3, 2025.

Proceeds from the placement will support the advancement of Argent BioPharma’s drug development pipeline, with a particular focus on advancement CannEpil ^® And clinical studies are planned.

The company is also conducting a comprehensive strategic review of its operational and management functions to ensure the long-term sustainability of its operations, which is pursuing a delisting from the London Stock Exchange and developing a work plan towards a US national listing.

Company Advisor: Sputnik Enterprises Limited He acted as the Company’s advisor for the IPO and will receive: a cash fee of 5% of the IPO proceeds, and 1,125,000 guarantees, subject to shareholder approval.

The release has been approved by the Board of Directors, for more information please contact:

on Argent Biopharma

ARGENT BIOPHARMA LIMITED (“the Company”) (ASX: RGT); (OTCQB: RGTLF) is an innovative, clinical-stage biopharmaceutical company specializing in neuroimmunology, developing advanced nanomedicines to address unmet medical needs in central nervous system (CNS) and immune disorders. Related terms. By leveraging cutting-edge technologies, including the neuroimmune modulation (NIM) system and its role in coordinating neuronal and immune responses, Argent BioPharma’s robust pipeline, which includes lead candidates such as CannEpil ^®Cognikan ^®And Symtra A ^®“Targets complex diseases that lack effective treatments. Through a commitment to science-based innovation and patient-focused outcomes, Argent BioPharma is reshaping the future of chronic, inflammatory and neurodegenerative disease care.

Follow us on our social media channels:

LinkedIn: Argent Biopharma
Twitter: @ArgentBioPharma
Facebook (NASDAQ:): Argent Biopharma